GlaxoSmithKline News

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Nov 27 06:13 ET

6-K: Blenrep Combinations Accepted for Review by the Us Fda for the Treatment of Relapsed/Refractory Multiple Myeloma

Nov 25 07:17 ET

6-K: Arexvy Approval Expanded to Adults Aged 50-59 at Increased Risk of Severe Rsv Disease in Japan

Nov 22 09:25 ET

6-K: Transaction Notification

Nov 19 10:56 ET

6-K: Linerixibat Shows Positive Phase Iii Results in Cholestatic Pruritus in Primary Biliary Cholangitis

Nov 19 08:11 ET

SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-GSK plc(9.5%)

Nov 15 16:24 ET

6-K: Lenrep Shows Overall Survival Benefit in Head-to-Head Dreamm-7 Phase Iii Trial for Relapsed/Refractory Multiple Myeloma

Nov 14 06:46 ET

6-K: Block Listing Six Monthly Return

Nov 13 10:17 ET

SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-GSK plc(11.2%)

Nov 12 16:39 ET

6-K: Transaction Notification

Nov 12 10:33 ET

6-K: Gsk Publishes Provisional Dividend Dates

Nov 12 09:48 ET

6-K: Total voting rights and capital

Nov 1 11:22 ET

6-K: Transaction notification

Oct 30 12:32 ET

6-K: Gsk on track to deliver 2024 outlooks with further good progress made in r&d

Oct 30 11:27 ET

6-K: New data for arexvy, gsk's respiratory syncytial virus vaccine, show potential to help protect a broader group of adults at increased risk for rsv disease

Oct 24 06:53 ET

6-K: Transaction Notification

Oct 17 12:07 ET

6-K: Transaction Notification

Oct 16 12:57 ET

6-K: Gepotidacin Accepted for Priority Review by Us Fda for Treatment of Uncomplicated Urinary Tract Infections in Female Adults and Adolescents

Oct 16 06:27 ET

6-K: Transaction Notification

Oct 15 06:40 ET

6-K: Gsk Announces Positive Phase Iii Results from Anchor Trials for Depemokimab in Chronic Rhinosinusitis with Nasal Polyps

Oct 15 06:18 ET